[ad_1]
KUALA LUMPUR, December 9 – The government said today that it will not compromise the safety, efficacy, and stability of Covid-19 vaccines, with a final decision on use subject to approval and registration by the National Drug Regulatory Agency ( NPRA). dependent on the Ministry of Health.
Science, Technology and Innovation Minister Khairy Jamaluddin said there will be no shortcuts in NPRA’s independent evaluation of clinical data.
“The government takes the issue of security very seriously. One of the main goals of the first two phases of the clinical trial is safety. Each vaccine must pass these two phases and must be proven safe before the vaccine enters phase three.
“At the moment, none of the Covid-19 vaccines in the phase three trials have sufficient data to demonstrate sterilizing immunity, showing that infections can be prevented. More information will be available as the trials progress, ”he said in a statement, in response to the statement by Gua Musang Member of Parliament (MP) Tengku Razaleigh Hamzah on Covid-19 vaccines.
The media reported that Tengku Razaleigh, in his comment on the recent agreement between the government and the pharmaceutical company Pfizer for the acquisition of the Covid-19 vaccine, said that the vaccine that had never before been used in humans was developed too quickly and that the government has a lot to answer for before allowing its use in Malaysia.
Khairy said the government’s estimated RM3 billion allocation may acquire enough doses to cover 70 percent of the population, not just 20 percent as Tengku Razaleigh alleges, and that the Pfizer deal clearly hasn’t exhausted all The assignment.
Khairy also noted that the Vaccine Safety Net (VSN) consists of a diverse group of websites that provide information on vaccine safety in multiple languages, evaluated by the World Health Organization and that meet the criteria for good information practice.
“Perhaps the Gua Musang MP would like to check the veracity of the resources he cites when preparing a statement,” he added.
In addition, Khairy said that the development of the Covid-19 vaccine has been accelerated due to several factors, mainly related to science and technology, which has evolved quite significantly over the last decade with new platforms such as messenger RNA (mRNA ) and the adenoviral vector. vaccinations
“These developments took place before the pandemic and were quickly adapted to develop a vaccine for Covid-19,” he said. – Bernama
